AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BIIB · NASDAQ · Drug Manufacturers - General

Biogen (BIIB)

Develops neurological medicines spanning MS, rare disease, Alzheimer’s, and complement-mediated conditions.

$222.31

vs last close+3.24 (+1.48%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	2,530	2,386	2,291	2,465	2,466	2,455	2,431	2,646	2,455	2,279	2,478	2,736
Cost of revenue	660	618	498	956	639	584	578	946	877	496	661	1,179
Gross profit	1,871	1,768	1,792	1,509	1,827	1,871	1,853	1,699	1,578	1,783	1,817	1,557
	1,550	1,256	1,102	1,143	1,250	1,362	1,121	1,111	964	1,840	1,419	1,239
Research & development	797	648	524	592	673	684	546	530	370	509	573	496
	753	608	578	550	577	679	575	581	595	683	607	710
Selling & marketing	0	71	0	0	0	67	0	0	0	0	0	0
General & administrative	0	537	0	0	0	612	0	0	0	683	0	0
Other expenses	0	0	0	0	0	0	0	0	0	648	239	34
Operating income	321	512	690	367	577	509	733	588	614	−57	397	318
	−462	−221	−226	332	−126	−218	−421	156	−57	−154	−20	−186
Interest income	96	24	17	20	12	19	24	32	32	37	38	25
Interest expense	64	72	69	61	60	60	60	73	67	68	68	82
Other non-operating income	50	51	58	−443	46	1	51	−328	−11	87	−20	103
Income before tax	−141	292	465	699	451	292	311	744	557	−211	378	132
Income tax expense	−73	43	71	115	63	25	71	109	91	−163	58	35
Net income from continuing operations	−68	249	393	584	389	267	241	635	467	−48	320	98
Net income	−68	250	393	584	389	267	241	635	467	−48	320	98
EPS, basic	−$0.47	$1.72	$2.71	$4.01	$2.67	$1.83	$1.65	$4.35	$3.18	−$0.33	$2.17	$0.66
EPS, diluted	−$0.47	$1.71	$2.70	$4.00	$2.66	$1.83	$1.64	$4.35	$3.17	−$0.33	$2.15	$0.66
Weighted average shares, basic	145	145	145	146	146	146	146	146	147	147	147	148
Weighted average shares, diluted	145	146	146	146	146	146	146	146	147	147	148	149
EBITDA	396	601	780	968	714	692	865	1,110	827	212	554	78
Depreciation & amortization	125	140	148	159	183	184	183	194	202	356	137	−137
EBIT	271	461	632	810	532	508	682	916	625	−144	417	215